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Background: Multiple myeloma (MM) is a neoplastic disorder of plasma cells interesting mainly the elderly. MM
remains an incurable disease, mostly because of the strong interplay between clonal plasma cells (cPCs) and bone
marrow (BM) microenvironment. Multiparameter flow cytometry (MFC) allows the simultaneous study of the cPC
immunophenotype and alterations involving other cells in BM, but rarely these data are interpreted as connected.
One exception to this habit are previous studies about relationship between CD117 cPC positivity and
hematopoietic progenitor cell (HPC) distribution in newly diagnosed patients. Thus we were interested in verifying
the distribution of BM CD34+ HPCs in healthy controls, and monoclonal gammopathy of undetermined significance
(MGUS) patients and various categories of responding/relapsing MM subjects divided according to CD117 positivity.
Results: Our data completely agree with precedent reports as regards untreated patients. In the group with
progression of disease, CD117- patients exhibited a lower CD34 + CD19-/CD34 + CD19+ ratio vs CD117+ subjects.
Among CD117- cases, newly diagnosed patients exhibited differences in distribution of HPCs vs responding myeloma
subjects and patients with progressive disease. These differences reached statistical significance comparing CD117-
newly diagnosed with CD117- responding cases, as reflected by CD34 + CD19-/CD34 + CD19+ ratio. In turn, no
differences emerged comparing CD117+ treated and untreated patients.
Conclusions: We demonstrate that administration of treatment and depth of reached response/presence of
relapse imply a distinct regulation in distribution of CD34+ HPC subsets in CD117- and CD117+ patients. These
differences become evident comparing untreated and treated CD117- patients, but they are impossible to detect
in CD117+ cases.
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Multiple myeloma (MM) is an incurable neoplastic
plasma cell disorder characterized by proliferation of
clonal/aberrant malignant plasma cells (cPCs) in bone
marrow, and presence of monoclonal immunoglobulin
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[1–3]. With a median age at diagnosis of 65–70 years [3],
MM is a disease affecting mainly elderly subjects. MM is
usually preceded by a premalignant PC proliferative stage
characterized by asymptomatic M-protein production
known as monoclonal gammopathy of undetermined sig-
nificance (MGUS), which is associated with a rate of pro-
gression to multiple myeloma of 1 % per year [4, 5]. In
MM long term control of the disease is still an elusive ob-
jective. Despite the dramatic progress in therapeutic ap-
proaches, due to the introduction of novel categories of
drugs (proteasome inhibitors and immunomodulatory
agents) [6], no curative strategies have currently beenticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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(HDT) and autologous stem cell transplantation (ASCT)
may experiment relapse [7, 8]. This phenomenon is
strictly related to the strong interplay between cPCs and
bone marrow (BM) microenvironment. Residual cPCs
may escape therapeutic effects in bone marrow niches,
which have been proved to be able to enhance cPC sur-
vival and modulate immune system ability to eradicate
malignant cells [3, 9, 10]. It has now become clear that, in
order to cure MM, targeting BM players other than MM
cells, and identifying the role of BM microenvironment in
response to therapeutic intervention are necessary. In
diagnosis and managing of MM and its preceding condi-
tion MGUS, multiparameter flow cytometry (MFC) plays
a key role, allowing enumeration of cPCs, and definition
of their immunophenotypic characteristics in comparison
with normal/reactive polyclonal plasma cells (nPCs). Al-
though MFC makes it possible to study simultaneously
the immunophenotype of cPCs and the alterations involv-
ing other cellular components in the BM microenviron-
ment in the same samples (belonging or not to the
immune system) [11–16], rarely these data are used to
make a connection between immunophenotypic PC char-
acteristics and modifications in BM populations. This is
true also in studies regarding hematopoietic progenitor
cell subset (HPC) distribution, which has been shown to
be impaired in MM patients at diagnosis and relapse [14–
16]. CD117 may be aberrantly expressed on cPCs in MM
and MGUS [11, 12, 17, 18], and positivity for this marker
confers a favourable prognosis [12, 17, 18]. Schmidt-
Hieber et al. [19] hypothesized that CD117 might act as
an anchor, favouring the adhesion of cPCs to myeloid
precursor-associated BM niches, with this interaction be-
ing mediated by c-kit ligand expressed by stromal cells
[19]; no clear mechanism has been defined yet. Previous
studies demonstrated that in newly diagnosed patients, no
differences were observed as regards CD34 + CD38-/dim
fraction, but the ratio between BM CD34 + CD19-CD38+
and CD34 + CD19 + CD38+ progenitors was increased in
CD117- patients compared to CD117+ subjects [19]. Des-
pite the recent augmented interest in hematopoietic pro-
genitor cell (HPC) distribution, depending on the debate
about the utility of quantification of HPC fractions in
grafts [20–22], observations about CD34 + CD19- and
CD34 + CD19+ subsets and related ratio (CD34 + CD19-/
CD34 + CD19+ ratio) were not examined in responding
and relapsing patients, and currently it is not known
whether differences in CD34 + CD19- and CD34 + CD19+
(Pro-B) cell fractions are preserved in treated patients or
may influence depth of response. In this study, we verified
distribution of BM CD34+ HPCs in healthy controls,
MGUS patients and various categories of responding/re-
lapsing MM subjects. Moreover, after dividing patients ac-
cordingly to CD117 expression or absence on PC surface,we compared differences in percentage of CD34 + CD19-
HPCs and Pro-B cells to detect a potential mechanism re-
lated to influence of CD117 positivity on prognosis.
Results
Characteristics of patients and plasma cell analysis
A total of 63 subjects (39 male and 24 female, no inter-
group significant differences) was included in this study.
Patients in Progressive group were significantly older
(75.13 ± 10.06 years) than Complete (61.1 ± 8.85 years,
p = 0.029) and Therapy (61.21 ± 9.01 years, p = 0.017)
subjects, while no significant differences emerged with
Control (62 ± 5.36 years), MGUS (70.8 ± 7.3 years) and
New (63.58 ± 12.8). Autologous stem cell transplant-
ation was performed in 6 Complete, 6 Therapy and 2
Progressive patients at least 12 months before the time
of this study (not significant). As regards therapeutic
regimen no statistically significant differences were de-
tected. Bortezomib + Dexamethasone based treatment
was administered to 5 Therapy and 3 Progressive pa-
tients. Thalidomide as monotherapy or in combination
with bortezomib was given to 1 Complete and 3 Ther-
apy patients respectively. Lenalidomide or lenalidomide
containing regimens were the treatment of choice in 4
Complete and 1 Progressive subjects, while Pomalido-
mide was administered to 1 Progressive patient. Finally, a
total of 13 patients (5 Complete, 6 Therapy and 2 Progres-
sive) underwent suspension of therapy for at least 15 days
before this study was perfomed. No differences emerged
for ISS staging at diagnosis (ISS I, 3 Complete, 3 Therapy
and 3 New; ISS II 7 Complete, 4 Therapy, 5 New and 5
Progressive; ISS III 7 Therapy, 4 New and 3 Progressive).
Instead as regards Durie-Salmon staging at diagnosis, the
cases were distributed as follows: IA, 2 Complete, 4 New
and 4 Progressive; IIA, 1 Complete, 5 Therapy, 5 New and
2 Progressive; IIB, 3 Therapy, 2 New and 2 Progressive;
IIIA, 6 Complete and 2 Therapy (Complete vs New, p =
0.018); IIIB, 1 Complete, 4 Therapy and 1 New.
According to literature [18], nPCs were always CD117-.
In turn, cPCs were CD117+ in 50 % (5) of MGUS, 42.86 %
(6) of Therapy, 59.17 (7) of New and 62.5 % (5) of Progres-
sive patients (not significant). Considering each group sep-
arately, characteristics of patients were homogeneous
comparing CD117- and CD117+ cases, except in group
New, in which none of CD117+ patients presented char-
acteristics of ISS III stage (vs 4/5 of CD117- patients, p =
0.01), and in group Progressive, in which CD117+ patients
were significantly older than CD117- ones (81.20 ± 4.09 vs
65 ± 8.66 years respectively, p = 0.01).
Significant differences were detected comparing me-
dian percentage of total PCs in New [8.64 % (0.26–
60.50 %)] and Progressive [6.47 % (0.75–30.29 %)] with
Control [0.15 % (0.01–1.71 %), vs New p < 0.0005, vs
Progressive p = 0.001], Complete [0.38 % (0.03–2.49 %),
Table 1 Intragroup comparisons between CD117+ and CD117-
cases for plasma cells
Group CD117+ cases CD117- cases p value
MGUS Tot PCs 1.30 1.48 NS
(0.71–2.40) (0.36–2.08)
nPCs 19.17 10.74 NS
(6.17–82.52) (5.24–51.64)
cPCs 80.83 89.26 NS
(17.48–93.83) (48.36–94.76)
Therapy Tot PCs 0.62 0.41 NS
(0.14–14.40) (0.12–1.15)
nPCs 25.19 71.79 NS
(0.14–70.80) (1.23–96.12)
cPCs 74.82 28.21 NS
(29.20–99.86) (3.88–98.77)
New Tot PCs 6.48 13.03 NS
(0.26–20.19) (0.44–60.50)
nPCs 1.68 0.32 0.01
(0.75–66.12) (0.05–1.32)
cPCs 98.32 99.68 0.01
(33.88–99.25) (98.68–99.95)
Progressive Tot PCs 2.14 9.03 NS
(0.75–30.29) (8.11–23.98)
nPCs 6.38 0.32 NS
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[0.48 % (0.12–14.40 %), vs New p = 0.012 and vs Progres-
sive p = 0.029], while no difference was observed with
MGUS [1.39 % (0.36–2.40 %)]. All PCs in Control and
Complete were polyclonal, whereas nPCs were 19.12 %
(5.24–82.52 %) in MGUS, 29.24 % (0.14–96.12 %) in
Therapy, 1.18 % (0.05–66.12 %) in New (vs Therapy p =
0.016), and 1.60 % (0.25–12.88 %) in Progressive. As
regards cPCs, New showed the most elevated median
percentage [98.83 % (33.88–99.95 %)] compared with
Therapy [70.76 % (3.88–99.86 %), p = 0.016], but no dif-
ference emerged in comparisons with MGUS [80.88 %
(17.48–94.76 %)] and Progressive [98.40 % (87.12–
99.75 %)]. As regards proportion of CD117+ cPCs, we
observed a trend depicting the highest percentage of
CD117+ plasma cells in MGUS and the lowest in Pro-
gressive (Fig. 1).
Intragroup comparisons between CD117+ and CD117-
cases as regards percentages of total plasma cells, nPCs
and cPCs are indicated in Table 1. In New, percentage of
nPCs was significantly higher and percentage of cPCs
was significantly lower in CD117+ cases vs CD117- ones.
The same picture was recorded in MGUS and Progres-
sive groups comparing CD117+ with CD117- patients,
although it did not reach statistical significance. Instead,
in Therapy group, we observed an extremely wide range
of percentages for both nPCs and cPCs in CD117- cases
in comparison with CD117+ patients.Fig. 1 Percentages of CD34 + cells (A), CD34+CD19- (B) and CD34
+CD19 + (C) fractions, and CD34 + CD19-/CD34 + CD19-ratios (D) for
all groups. Box plots indicate the median and 25th and 75th
percentiles. Whiskers indicate minimum and maximum values.
•,* = outliers. * indicate values that are more distant than 1.5
interquartile ranges considering the nearest edge of the represented
box; • indicate values that are more distant than 3 interquartile ranges
considering the nearest edge of the represented box, as reported in
Ref. [31]. The Kruskal-Wallis statistic test with pairwise comparisons was
used for this analysis; p values of pairwise comparisons are indicated
(0.59–12.88) (0.25–1.67)
cPCs 93.62 99.68 NS
(87.12–99.41) (98.33–99.75)
Results are expressed as median percentage (range)
Tot PCs total plasma cells, nPCs normal/reactive polyclonal plasma cells (out of
total plasma cells), cPCs clonal/aberrant plasma cells (out of total plasma cells),
NS not significant
The Mann-Whitney U-test was used for this analysisRelationship between CD117 positive and negative cPCs
and CD34+ bone marrow HPCs
No statistical significant differences emerged comparing
percentage of total CD34+ HPCs, CD34 + CD19+ cells
(out of total CD34+ HPCs) and CD34 + CD19- cells (out
of total CD34+ cells), as well as CD34 + CD19-/CD34 +
CD19+ ratio, despite the fact that Therapy exhibited the
highest CD34 + CD19+ fraction and the lowest CD34 +
CD19- fraction and CD34 + CD19-/CD34 + CD19+ ratio
(Table 2). Performing intragroup comparisons between
CD117+ vs CD117- cases, we noticed that Therapy
CD117- patients showed a higher percentage of total
CD34+ cells compared to Therapy CD117+ patients. In
New, CD117+ subjects exhibited a higher percentage of
total CD34+ and CD34 + CD19+ cells vs CD117- pa-
tients; in turn, CD117- cases showed a more extended
proportion of CD34 + CD19- cells and a higher CD34 +
CD19-/CD34 + CD19+ ratio. The frame seemed to be
Table 2 Percentages of total CD34+ cells and CD34+ fractions
Tot CD34+ CD34 + CD19- CD34 + CD19+ Ratio
Control 1.17 85.74 14.26 6.01
(0.72–2.17) (72.94–90.62) (9.38–27.06) (2.70–9.66)
MGUS 1.34 88.51 11.49 7.82
(0.30–2.46) (82.58–97.99) (2.01–17.42) (4.74–48.75)
Complete 1.98 88.10 11.91 18.75
(0.45–8.26) (24.18–98.75) (1.25–75.97) (0.32–79)
Therapy 1.28 73.12 26.88 2.73
(0.14–2.84) (33.91–98.71) (1.29–66.09) (0.51–76.52)
New 1.26 87.11 12.90 6.77
(0.06–2.61) (74.98–98.89) (1.11–25.02) (3–89.09)
Progressive 0.70 84.24 15.76 5.66
(0.22–0.87) (75.73–94.83) (5.17–24.27) (3.12–18.34)
Results are presented as median values (range)
Tot CD34+, total CD34+ hematopoietic progenitor cells; CD34 + CD19-, fraction of CD34 + CD19- cells (out of total CD34+ cells); CD34 + CD19+, fraction of CD34 +
CD19+ cells (out of total CD34+ cells); Ratio, CD34 + CD19-/CD34 + CD19+ cellular fraction ratio
The Kruskal-Wallis statistic test with pairwise comparisons was used for this analysis (no significant results)
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higher median fraction of CD34 + CD19- cells, and
CD117- presented a higher median CD34 + CD19+ per-
centage and a lower CD34 +CD19-/CD34 +CD19+ ratio
(Table 3). Similarly in MGUS and Therapy, median per-
centage of CD34 +CD19- progenitors was larger and me-
dian percentage of CD34 + CD19+ cells was reduced
comparing CD117- cases vs CD117+ ones (Table 3, not
statistically significant). Exploring relationship be-
tween percentage of CD117+ cPCs and CD34 +
CD19-/CD34 + CD19+ ratio, Spearman’s correlation
coefficients were −0.718 (p = 0.009) for New, and
0.952 (p < 0.0005) for Progressive. To further deepen
how CD117 positivity or negativity may influence dis-
tribution of HPCs, we compared Control and
Complete data with results obtained from patients in
all groups divided according to presence or absence of
CD117 on cPC surface. When we compared results
from Control, Complete and CD117- cases (Fig. 2a–d),
we noticed that CD117- New cases showed the lowest
percentage of total CD34+ BM cells compared to
Complete and CD117- Therapy patients. In turn, per-
centage of CD34 + CD19- cells was higher in CD117-
New vs CD117- Therapy (p = 0.014) and Progressive
(not significant) subjects (Fig. 2b), while inverted situ-
ation was recorded for CD34 + CD19+ cells, with
CD117- New cases depicting a reduced percentage of
these progenitors in comparison with Therapy (p =
0.014) and Progressive (not significant) patients
(Fig. 2c). As expected, CD34 + CD19-/CD34 + CD19+
ratio was increased in CD117- New subjects vs Ther-
apy and Progressive (Fig. 2d). When we compared
Control, Complete and CD117+ cases, no statistical
significant differences were observed (Fig. 2a–d).Discussion
The interaction of cPCs with BM microenvironment is
fundamental to ensure development and progression of
MM. Destruction of BM homeostasis, by a complex sys-
tem of direct, autocrine and paracrine interactions be-
tween components of the BM microenvironment and
cPCs, influences proliferation and triggering of anti-
apoptotic mechanisms [3, 10]. Normal hematopoiesis is
impaired in MM subjects, with anemia being one of
MM characteristic clinical features [8]. Precedent studies
demonstrated alterations in BM distribution of HPCs in
MM subjects. Compared to healthy donors, a substantial
reduction of CD34+ HPC subsets and CD19 + CD38 +
CD34+ Pro-B cells in terms of absolute cell count and
proportion of mononuclear cells respectively was de-
scribed in untreated MM subjects [15]. Similarly, per-
centage of total CD34+ cells and CD34 + CD19+ cells
(both defined as proportion of total leukocytes excluding
PCs) was proven to be decreased at presentation and re-
lapse, but not in patients at plateau/remission, vs normal
individuals [14]. Coherently, a more recent report con-
firmed reduction of percentage of CD34+ HPCs (from
whole BM cellularity) and CD34 + CD38 + CD19+ pro-
genitors (out of total CD34+ HPCs) in BM of MM pa-
tients vs healthy controls [16]. In all listed studies, no
categorization of patients on the basis cPC immunophe-
notype was performed. In newly diagnosed patients, di-
vided accordingly to CD117 positivity and negativity, the
percentage of CD34 + CD19 + CD38+ progenitor cells
was reported to be higher in CD117+ vs CD117- cases,
leading to a significant decrease in CD34 + CD19-/
CD34 + CD19+ ratio [19]. On the basis of precedent re-
ports, we were interested in exploring the relationship
between presence/absence of CD117 on cPCs surface
Table 3 Intragroup comparisons between CD117+ and CD117-
cases for total CD34+ cells and CD34+ fractions
Group CD117+ CD117- p value
MGUS Tot CD34+ 1.47 1.19 NS
(0.50–2.46) (0.30–1.63)
CD34 + CD19- 95.49 86.72 NS
(82.58–97.99) (85.73–96.34)
CD34 + CD19+ 4.51 13.28 NS
(2.01–17.42) (3.66–14.27)
Ratio 21.17 6.53 NS
(4.74–48.75) (6.01–26.32)
Therapy Tot CD34+ 0.73 1.83 0.013
(0.14–2) (0.85–2.84)
CD34 + CD19- 78.71 70.97 NS
(33.91–98.71) (62.86–91.42)
CD34 + CD19+ 21.29 29.04 NS
(1.29–66.09) (8.58–37.14)
Ratio 4.27 2.50 NS
(0.51–76.52) (1.69–10.66)
New Tot CD34+ 1.80 0.56 0.018
(0.49–2.61) (0.06–1.22)
CD34 + CD19- 82.42 94.59 0.003
(74.98–87.70) (90–98.89)
CD34 + CD19+ 17.58 5.41 0.003
(12.30–25.02) (1.11–10)
Ratio 4.69 17.48 0.003
(3–7.13) (9–89.09)
Progressive Tot CD34+ 0.80 0.60 NS
(0.22–0.87) (0.23–0.62)
CD34 + CD19- 88.75 77.88 0.036
(80.79–94.83) (75.73–80.77)
CD34 + CD19+ 11.25 22.12 0.036
(5.17–19.21) (19.23–24.27)
Ratio 7.89 3.52 0.036
(4.21–18.34) (3.12–4.20)
Results are expressed as median percentage (range)
Tot CD34+, total CD34+ hematopoietic progenitor cells; CD34 + CD19-, fraction
of CD34 + CD19- cells (out of total CD34+ cells); CD34 + CD19+, fraction of
CD34 + CD19+ cells (out of total CD34+ cells); Ratio, CD34 + CD19-/CD34 +
CD19+ cellular fraction ratio
The Mann-Whitney U-test was used for this analysis
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subsets in MGUS, newly diagnosed, stringent complete
responders, treated (but not complete responder) pa-
tients, and subjects with progressive disease. We did not
observed significant differences in frequency of CD117
positivity comparing all categories of patients, contradic-
ting previous reports [18]. However this discrepancy
could be related to variations in sample size. In New,only CD117- were classified as stage ISS III, while none
of CD117+ cases showed association with the most ad-
vanced ISS stage. These data, together with the trend ex-
hibited by CD117+ cPCs (the highest percentages
recorded in MGUS, decreasing through Therapy and
New, to the most reduced fraction observed in Progres-
sive) strongly recalls the association of CD117 negativity
with features of a more aggressive disease in MM [17],
and supports the hypothesis that CD117+ clones might
be deleted during progression [18]. In intragroup com-
parisons of percentages of total, normal and clonal PCs,
we observed that in New CD117+ patients nPCs were
significantly higher and cPCs were significantly lower vs
New CD117- subjects, accordingly to precedent reports
[19]. No significant differences were observed in other
groups, but the exact mechanism ruling expansion of
cPCs vs nPCs remains to be elucidated. As regards dis-
tribution of CD34+ HPCs, we did not recorded general
variations in percentage of CD34+ HPCs, and CD34 +
CD19- and Pro-B cell subsets comparing all groups
among them. This is openly conflicting with precedent
papers [14–16], but may be easily explained considering
three important factors: 1) the studies were conducted
following different methods of measuring and expressing
fractions of CD34+ HPCs; 2) the statistical analysis was
performed through different tests (we needed to use spe-
cific tests for multiple comparisons); 3) patients were
not divided in groups according to the immunopheno-
type of cPCs, so we cannot evaluate carefully the impact
of CD117 positivity on previously reported data. In fact,
carrying on our analysis, we noticed that CD117 has a
strong influence on CD34+ HPC distribution both in
New and Progressive groups, but with different out-
comes. In New our findings are consistent with those
described by Schmidt-Hieber et al. [19], with a signifi-
cant inverse correlation between CD117 positivity and
CD34 + CD19-/CD34 + CD19+ ratio. Instead, the oppos-
ite situation was recorded in Progressive, with a signifi-
cant direct correlation between CD117 and CD34 +
CD19-/CD34 + CD19+ ratio, reflected by detected mea-
sured fractions of CD34 + CD19- and Pro-B cells. Inter-
estingly, also in Therapy and MGUS groups we
evidenced that CD117 positivity is associated with a re-
duction in median percentage of CD34 + CD19+ HPCs
and an increase in median percentage of CD34 + CD19-
cells, although this results did not reach statistical sig-
nificance. A previously elaborated hypothesis underlined
the possibility that CD117+ cPCs may consume stem
cell factor and occupy BM stem cell niches, thus per-
turbing normal hematopoietic process [19]. Moreover,
the same authors proposed that in CD117+ patients,
nPCs may exert a more pronounced homeostatic role in
comparison with CD117- subject; this property of nPCs
may be a function of the adhesive action of CD117+ on
Fig. 2 Percentages of CD34+ cells (a), CD34+CD19- (b) and CD34+CD19+ (c) fractions, and CD34 + CD19-/CD34 + CD19- ratios (d) for all groups.
Box plots indicate the median and 25th and 75th percentiles. Whiskers indicate minimum and maximum values. •,* = outliers. * indicate values
that are more distant than 1.5 interquartile ranges considering the nearest edge of the represented box; • indicate values that are more distant
than 3 interquartile ranges considering the nearest edge of the represented box, as reported in Ref. [31]. The Kruskal-Wallis statistic test with
pairwise comparisons was used for this analysis; p values of pairwise comparisons are indicated
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sor niches [19]. Our data suggest that in MGUS and
Therapy patients the presence of an extended amount of
nPCs may counteract the effect on HPCs mediated by
expansion of CD117+ cPCs, whereas in Progressive pa-
tients the percentage of CD117+ cPCs is so small (Fig. 1)
that it cannot exert the same modulation on HPCs ob-
served in New subjects. However, given the small sample
size, confirmation by a larger cohort of patients is rec-
ommendable. The most surprising results emerged from
analysis of Control and Complete data with measured
values for CD117- cases. Total CD34+ HPCs were less
expanded in CD117- New vs both Complete andCD117- Therapy subjects, thus reflecting a possible
reorganization of BM niches in patients able to respond
to treatment. Moreover, significant differences were ob-
served between CD117- New and Therapy patients, with
New displaying a more extended CD34 + CD19- fraction
and a reduced Pro-B population compared to Therapy.
This was concretized in a higher CD34 + CD19-/CD34 +
CD19+ ratio in CD117- New cases vs CD117- Therapy
patients. Similar differences in CD34 + CD19- and
CD34 + CD19+ HPC distribution emerged comparing
CD117- New with CD117- Progressive patients, but stat-
istical significance was not achieved. In turn, when we
compared Control, Complete and CD117+ subjects, no
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and CD34 + CD19+ cells emerged. These pieces of in-
formation are extremely intriguing, since they clearly
demonstrate administration of treatment and depth of
reached response/presence of relapse imply a distinct
regulation in distribution of CD34+ HPC subsets in
CD117- and CD117+ patients. Such a alteration in BM
stem cell niche composition clearly rises comparing un-
treated and treated CD117- patients, but it is impos-
sible to detect in CD117+ cases. Given that significant
alterations in distribution of CD34+ HPC subsets ex-
clusively regards patients unable to reach complete re-
sponse, it will be interesting to evaluate the influence of
other immunophenotypes (not described in this studies)
on the ability of CD117- patients to achieve a deeper re-
sponse. In addition, a possible future step might be the
study of an eventual correlation between plasma cell
immunophenotypic characteristics and mobilization/graft
contents.
Conclusions
In conclusion, we confirmed previous trends in CD34+
HPC subset distribution in newly diagnosed patients di-
vided according to CD117 positivity. Moreover, we pro-
vided some insights in CD34+ HPC distribution in
relapsing patients. We also describe different impact of
treatment on CD34+ HPCs in CD117- patients vs
CD117+ subjects, thus opening the debate about effect
of CD117 on mechanism determining prognosis.
Methods
Patients and BM samples
Control specimens consisted of 9 BM samples from pa-
tients who were suspected to have a haematological dis-
ease and revealed to be non onco-hematological subjects
(group Control). These patients have no history of MM,
MGUS or lymphoid/myeloid neoplasm. BM samples of
44 patients with MM and 10 patients with MGUS sub-
mitted to our laboratory for routine analysis were evalu-
ated by MFC. For every patient clinical chemical and
immunological profiles, as well as reference intervals
were provided by the U.O. Patologia Clinica - Labora-
torio Analisi Cliniche of ARNAS Civico, Palermo (Italy).
Disease stage was defined according to Durie-Salmon
and ISS staging criteria [23, 24]. Response to therapy
was defined conforming to Bird et al. [25]. Of MM sam-
ples, 12 were obtained at presentation (group New), 8
from patients with progressive disease (group Progres-
sive), 14 from patients unable to reach complete re-
sponse (4 Very Good Partial Response, 6 Partial
Response and 4 Stable Disease - group Therapy) and 10
from patients who achieved stringent CR (group
Complete). MGUS patients were considered as a separ-
ate group (group MGUS). Clinical data and history forMGUS and MM cases were provided by U.O. Oncoe-
matologia of ARNAS Civico, Palermo (Italy). Informed
consent procedures and forms were proposed to and
approved by the ARNAS Civico Medical Ethics Com-
mittee. Written informed consent was given by all sub-
jects in line with the Declaration of Helsinki. BM
samples were collected in EDTA tubes and processed in
one hour since collection.
Multiparameter flow cytometry
Details about antibodies and instrument are indicated in
Tables S1 and S2 respectively [see Additional file 1].
Specimens were fragmented with a sterile syringe and
filtered using a 80 μm filter; nucleated cells were
enumerated using UniCel® DxH™ 800 Coulter® Cellular
Analysis System (Beckman Coulter, Miami, FL, USA) and
brought to a final concentration of 106cells/100 μl with
PBS w/o calcium and magnesium (EuroClone, Milan,
Italy). To stain surface and intracellular markers, the
following combinations of antibodies were used: Tube 1,
CytκFITC/CytλPE/CD38PC5.5/CD56PC7/CD138APC/CD27APC-
AlexaFluor 750/CD19PB/CD45KO; Tube 2, CD27FITC
# /CD56PE/
CD38PC5.5/CD117PC7/CD138APC/CD34APC-AlexaFluor 750/
CD19PB/CD45KO (Cyt, Cytoplasmic; FITC, Fluorescein
Isothiocyanate; PE, R-Phycoerythrin; PC5.5, R-Phycoery
thrin-Cyanin 5.5; PC7, R-Phycoerythrin-Cyanin 7; APC,
Allophycocyanin; PB, Pacific Blue; KO, Krome Orange). All
antibodies were purchased from Beckman Coulter (Miami,
FL, USA), except for # which was purchased from BD
Biosciences (San Jose, CA, USA). For staining of surface
markers, 100 μl of each sample were incubated with the op-
portune combinations of antibodies for 15 min in the dark.
Erythrocytes were lysed adding 1 ml of VersaLyse™ Lysing
Solution and incubating tubes for 20 min in the dark. For
intracellular staining of kappa and lambda light chains,
50 μl of sample were washed 5 times with 2 ml of PBS w/o
calcium and magnesium (EuroClone, Milan, Italy), and
processed with PerFix-nc (Beckman Coulter, Miami, FL,
USA) following instructions. Samples were all acquired
with Navios™ Flow Cytometry System, data were collected
with Navios v1.0 Software (Beckman Coulter, Miami, FL)
and then analyzed with Kaluza® Flow Cytometry Analysis
Software v1.3 (Beckman Coulter, Miami, FL, USA). Daily
testing of instrument was performed as indicated: stan-
dardization of light scatter, fluorescence intensity and
optimal hydrodynamic focusing instrument settings
were verified using Flow-Set Pro Fluorospheres (Beckman
Coulter, Miami, FL, USA); compensation matrix for each
combination of antibodies was tested with CYTO-
COMP™ Cell Kit (Beckman Coulter, Miami, FL, USA);
optical alignment and fluidics were checked using Flow-
Check Pro Fluorospheres (Beckman Coulter, Miami, FL,
USA). In order to identify PCs, a combination of CD38,
CD138 and CD45 together with light scatter properties
Pojero et al. Immunity & Ageing  (2015) 12:5 Page 8 of 9was used; the first gate was set on CD38 vs CD138 as
suggested [11]. Distinction between normal/reactive and
clonal plasma cell compartments was performed basing
on their most frequent aberrant phenotypes (CD38,
CD19, CD27, CD117, CD56 and CD45); results were con-
firmed by the presence of clonal restriction in population
showing the abnormal phenotype, and the absence of re-
striction in normal PCs [11, 26]. The κ:λ ratio was defined
as abnormal if < 0.5 or > 3 [27]. A minimum of 200 events
in the plasma cell gate and 500 events in CD34+ gate on
the CD34/SSC plot were collected for each tube; in order
to reach this result, a total of 200,000–2,000,000 events
were acquired. For each marker, an internal negative
population present within the sample was used to define
gates and sample fluorescence background [28, 29]. Re-
sults for total PCs and CD34+ HPCs are expressed as per-
centage of cells out of total acquired cells. Data for cPCs
and nPCs are indicated as percentage of cells out of total
PCs. Fractions of CD34 + CD19- and CD34 + CD19+ cells
are reported as percentage of cells out of total CD34+
HPCs. CD34 + CD19+ Pro B cells were identified through
the available markers accordingly to their recognized
immunophenotype [30].
Statistical analysis
Continuous non normal data are expressed as median
values (range); normal variables are indicated as mean ±
SD. Baseline differences between groups were assessed by
the chi-square test or Fisher’s exact test, as needed for
categorical variables (with Bonferroni correction for
multiple comparisons). The univariate analysis of vari-
ance (ANOVA) was performed for parametric variables,
and post hoc analysis with the Tukey’s test was used to
determine pairwise differences. The Mann-Whitney U-test
was used for intragroup analysis. The Kruskal-Wallis stat-
istic test with pairwise comparisons was performed for
nonparametric analysis. Spearman’s correlation analysis
was performed to assess the statistical association between
variables. Data were analyzed by IBM SPSS Software 22
version (IBM Corp., Armonk, NY, USA). All p-values were
two-sided and p < 0.05 was considered statistically signifi-
cant. Graphics were interpreted and presented according
to published conventions [31].
Additional file
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